or Connect
HotStockMarket › Forums › HSM Stock Forum › Stock Message Boards NYSE, NASDAQ, AMEX › VNDA - Vanda Pharmaceuticals Inc
New Posts  All Forums:Forum Nav:

VNDA - Vanda Pharmaceuticals Inc - Page 10

post #181 of 196
Quote:
Originally Posted by Norlan View Post
Vanda Pharma (VNDA) Executives Cash Out Following 1000% Surge In The Stock After FDA Okay:

http://www.streetinsider.com/Insider...y/4648093.html

this sounds like about to trigger a bling to me
post #182 of 196
So they sold off some of their shares that vested after the drug approval? Between the two of them they only sold around 32k shares, that's nothing. Now, if Tang Capital sold off all their shares, I'd take note.

GM insiders are cashing out of a worthless company. VNDA has an approved anitphyscotic drug. Do any of you know anything about this? It's a multi-billion dollar market. Also, the $12 price target that is currently out there, is only on the tablet form of the drug, they aren't even taking into account the development of the injectionable form. Also, the $12 prices takes into account that they try to sell it themselves and not partner. Looking forward to other analysts initiating coverage.

Doctors often prescribe new antipsychotics to patients as they lose effectiveness and they switch to a new drug. With VNDA's Fanapt the efficacy is on par, if not slightly lower, but the side effects are much lower than others. I see this as a great alternative.

Needless to say I'm long. Probably end up holding on until december to see how sales are shaping up. Still curious to see whether they will Partner or try to sell it themselves.

http://www.fanapt.com/
post #183 of 196
Quote:
Originally Posted by ioaz View Post
So they sold off some of their shares that vested after the drug approval? Between the two of them they only sold around 32k shares, that's nothing. Now, if Tang Capital sold off all their shares, I'd take note.

GM insiders are cashing out of a worthless company. VNDA has an approved anitphyscotic drug. Do any of you know anything about this? It's a multi-billion dollar market. Also, the $12 price target that is currently out there, is only on the tablet form of the drug, they aren't even taking into account the development of the injectionable form. Also, the $12 prices takes into account that they try to sell it themselves and not partner. Looking forward to other analysts initiating coverage.

Doctors often prescribe new antipsychotics to patients as they lose effectiveness and they switch to a new drug. With VNDA's Fanapt the efficacy is on par, if not slightly lower, but the side effects are much lower than others. I see this as a great alternative.

Needless to say I'm long. Probably end up holding on until december to see how sales are shaping up. Still curious to see whether they will Partner or try to sell it themselves.

http://www.fanapt.com/
Bottom line is, I don't put long term faith in biotech stocks personally, unless if you bought it at pennies or when you're waiting on FDA approval
post #184 of 196
Quote:
Originally Posted by Norlan View Post
Bottom line is, I don't put long term faith in biotech stocks personally, unless if you bought it at pennies or when you're waiting on FDA approval
But then you're straight up gambling... The only reason I was in the company at .95 was because I was looking to profit after the assumed denial by the FDA again(how likely was it that the FDA would change their mind, regardless of the efficacy of the drug), then profit when the company was forced to liquidate. Where it stood it was worth more even after paying all liabilities, etc. Tang Capital even initiated a proxy fight to move for that to happen.

I guess we have different investment strategies.
post #185 of 196
Apparently I'm the only one following this stock, but we hit a new intraday 52wk high today and saw a couple upgrades this week. One is $22 and the other (though I haven't seen it, but you apparently can if you have a subscription to morningstar) is $20. They are about $30 if they get bought out, but I'd be surprised if that happened.

Natixis says $12 if they go it alone, $22 if they partner(which they believe and that's where the target comes from) and $30 if they get bought out. Almost no long run downside IMHO, barring horrible things... you know how the market is
post #186 of 196
HOD 14.79

what's the target price by the consensus, anyone know?
post #187 of 196
dude.. you the post right after the answer the your question
post #188 of 196
Quote:
Originally Posted by Norlan View Post
HOD 14.79

what's the target price by the consensus, anyone know?

Right now, there are only the 2 price targets I mentioned, so I guess consensus is $21.
post #189 of 196
anyone know where the support floor is? 10?
post #190 of 196
Quote:
Originally Posted by Norlan View Post
anyone know where the support floor is? 10?
7.50ish. It tried to breakdown below that after the big gap up and couldn't do it. The spreads on this are fairly wide and the price can bounce around all day. I missed the boat on some June 12.50 calls. I almost bought them for .95 a few weeks ago. They were trading around 2.50 last week. I still have some 5x lotto puts that will probably expire worthless.
post #191 of 196
Nice AH spread and increase today. If the PM activity looks similar there could be a good entry opportunity.
post #192 of 196
I really don't understand this. They put out a really great PR and the stock tanks? It really dumbfounds me.
post #193 of 196
Analysts estimate that VNDA target share price is upgraded to $17 - $24 due to its recent agreement with Novartis.

Vanda (VNDA) will receive an upfront payment of $200 million and will be eligible for more payments totaling up to $265 million at certain milestones. Vanda also will receive royalties on the U.S. and Canadian net sales of Fanapt.

This will make the target share price of VNDA to be around $17-$24.


Vanda Pharma, Novartis To Develop, Sell Schizophrenia Drug - WSJ.com

Vanda Pharmaceuticals Inc. (VNDA) has entered into an agreement with Swiss drug maker Novartis AG (NVS) to commercialize and develop its schizophrenia drug Fanapt in the U.S. and Canada.

Novartis said it expects to launch the drug in the U.S. early next year.

In May, Vanda pulled off an upset by winning U.S. regulatory approval to sell a drug most investors had abandoned. The U.S. anti-psychotic market is about $14 billion.

Shares of the tiny Rockville, Md., company jumped 14% to $13 after-hours. The stock is up more than 10 times in the past year.

Novartis shares rose 1 cent to $50.63 in after-hours trading. That stock is up 15% in the past year.

Under the agreement, which amended a prior deal between the companies, Novartis will have exclusive rights to commercialize Fanapt for the U.S. and Canada. Novartis will develop and commercialize a long-acting injectable version of the drug.

Vanda will receive an upfront payment of $200 million and will be eligible for more payments totaling up to $265 million at certain milestones. Vanda also will receive royalties on the U.S. and Canadian net sales of Fanapt.

The deal is expected to receive the required approvals by the end of the year.

Vanda will retain rights to commercialize Fanapt oral and depot formulations outside the U.S. and Canada. At Novartis' option, the companies will discuss the commercialization of Fanapt outside of the U.S. and Canada or Novartis will receive a royalty on net sales.

"With the launch of Fanapt in early 2010, we will broaden our presence in psychiatry and build on the heritage of Novartis in offering innovative treatments for devastating psychiatric diseases," said Ludwig Hantson, chief executive of Novartis Pharmaceuticals Corp.



-By Kathy Shwiff, Dow Jones Newswires; 212-416-2357; Kathy.Shwiff@dowjones.com
post #194 of 196
VNDA is moving. Could be a good late Dec early Jan play

11:45 (Dow Jones) Jefferies is stunned that Vanda Pharma (VNDA) has an enterprise value of only about $100M. The firm starts VNDA at buy, noting it has an approved drug - schizophrenia treatment Fanapt - in a $10B category, with a differentiated profile, being sold by Novartis (NVS:$54.24,00$-0.44,00-0.80%) . The firm thinks the January launch of Fanapt could make its $22 target a reality.

If it can break 12.00 it will have momentum
post #195 of 196

no one comenting this?

post #196 of 196
Zzzz

Sent from my GT-I9100 using Tapatalk
New Posts  All Forums:Forum Nav:
  Return Home
HotStockMarket › Forums › HSM Stock Forum › Stock Message Boards NYSE, NASDAQ, AMEX › VNDA - Vanda Pharmaceuticals Inc